Home › Selling a Home Health Agency in 2026

Selling a Home Health Agency in 2026

Quick Answer

A home health agency (Medicare-certified skilled home health), private-duty home care, or hospice agency in 2026 typically sells in these ranges: skilled home health roughly 7x to 9.5x EBITDA for quality mid-market agencies (smaller agencies 4x-7x; large multi-state platforms higher), private-duty home care roughly 4x to 8x EBITDA, and hospice roughly 9x to 12.5x EBITDA (hospice commands the highest multiples in the sector). The biggest value drivers are payer mix and revenue quality (Medicare-certified skilled home health and hospice are valued well above purely private-pay or Medicaid-heavy home care; clean billing and a low PEPPER/audit risk profile matter enormously), scale and geographic density, census stability and referral-source diversity (no single hospital or facility dominating admissions), caregiver and clinician recruitment and retention (staffing is the binding constraint), state licensure and any certificate-of-need value (in CON states, the license itself carries value and limits new competition), and quality scores (star ratings, survey history). Active buyers include PE-backed home-based-care platforms, large national home health and hospice companies, payers building care-at-home, health systems, and regional consolidators. Several buyers in CT’s network have mandates for home health, contract therapy, geriatric care, and pediatric home health. Most home health agency sales close in 90 to 210 days.

Home-based care, skilled home health, private-duty home care, and hospice, has been a magnet for private equity and strategic buyers for years, the population is aging, payers want care delivered at home, and the sector is fragmented. But the multiples vary widely by segment: hospice trades highest, Medicare-certified skilled home health next, private-duty home care lowest, and within each segment payer mix, scale, census stability, staffing, licensure, and quality scores swing the number significantly. This guide covers the multiples by segment, the value-driver math, the PE-backed and strategic buyers, what kills deals in diligence, and the process.

We are CT Acquisitions, a buy-side M&A advisory firm with buyers in our network actively acquiring home health agencies, home care companies, contract therapy businesses, and related home-based-care providers (several with mandates for home health, geriatric care, and pediatric home health). Sellers pay nothing, the buyer pays our fee at closing. See also our guides on selling a behavioral health practice, selling an ABA therapy business, and healthcare business valuation.

Free Valuation Tool → Book a 30-Min Call Read: Broker Alternative

What this guide covers

Private-duty home care agency: typically 4x to 8x EBITDA (depends on scale, payer mix, caregiver retention)
Medicare-certified skilled home health agency: roughly 7x to 9.5x EBITDA for quality mid-market agencies (smaller 4x-7x, large platforms higher)
Hospice agency: roughly 9x to 12.5x EBITDA, the highest-multiple segment in home-based care
Biggest value drivers: payer mix and billing/audit risk profile, scale and density, census stability and referral-source diversity, caregiver/clinician retention, state licensure and CON value, and quality scores
Active buyers: PE-backed home-based-care platforms, large national home health and hospice companies, payers building care-at-home, health systems, regional consolidators; we have buyers in our network
Free valuation: our 90-second tool applies home-based-care-specific adjustments for segment, payer mix, census, staffing, and licensure

What home health and hospice buyers actually pay for in 2026

Private-duty home care agency

Typical multiples: 4x to 8x EBITDA. Non-medical or limited-medical home care, often a mix of private-pay, long-term-care insurance, Medicaid waiver, and VA. Buyer pool: PE-backed home care platforms, larger home care companies, regional consolidators, individual operator-buyers. Multiples reach the upper end with scale, a favorable payer mix (more private-pay and insurance, less thin-margin Medicaid), strong caregiver recruitment and retention, diversified referral sources, and clean financials. Franchise units trade within their system’s typical band.

Medicare-certified skilled home health agency

Typical multiples: roughly 7x to 9.5x EBITDA for quality mid-market agencies; smaller agencies 4x-7x; large multi-state platforms higher. The Medicare certification, the clinical infrastructure, and the referral relationships make these worth more than private-duty care. PE-backed home-based-care platforms, large national home health companies, payers, and health systems compete here. Multiples reach the upper end with scale and density, a clean billing and audit-risk profile (low PEPPER outlier risk, clean survey history), strong star ratings, diversified referral sources, stable census, and good clinician retention.

Hospice agency

Typical multiples: roughly 9x to 12.5x EBITDA, the highest-multiple segment in home-based care, driven by demographics, the per-diem payment model, strong margins at scale, and intense buyer competition. The same drivers apply, scale, clean billing and audit profile (length-of-stay and live-discharge metrics are scrutinized hard), referral-source diversity, census stability, licensure/CON value, and survey history. Hospice diligence is especially focused on regulatory and billing risk because of the enforcement environment.

The value-driver math

Factor	Why it moves the multiple
Segment (hospice > skilled home health > private-duty home care)	Different payment models and margin profiles; hospice’s per-diem economics and demographics put it at the top
Payer mix (Medicare/hospice and private-pay/insurance vs thin-margin Medicaid)	Higher-margin, more durable revenue; Medicaid-heavy books carry rate and reimbursement risk
Clean billing + low audit/PEPPER risk + good survey history	The single biggest diligence area in home health and especially hospice; outlier metrics or survey deficiencies reprice or kill deals
Scale and geographic density	Operating leverage, route density, easier to manage, more strategic to platform buyers; multi-state with CON value is premium
Census stability + diversified referral sources	No single hospital, SNF, physician group, or facility dominating admissions; durable, predictable volume
Caregiver / clinician recruitment and retention	Staffing is the binding constraint; an agency that can recruit and keep nurses, therapists, aides is a growth platform
State licensure / certificate of need (in CON states)	The license itself carries value and limits new competitor entry; a scarce asset in CON states
Quality scores (star ratings, CAHPS, survey history)	Affect referrals, payer relationships, and (for some payers) reimbursement; signal operational quality

The pattern: home-based-care value is a function of which segment you’re in, how clean and low-risk your billing and survey profile is, how scaled and dense your operations are, how diversified your referral base is, how well you staff, and what your licensure is worth. The biggest controllable lever before a sale is the billing/audit/survey risk profile, get that clean.

The buyers acquiring home health and hospice agencies in 2026

PE-backed home-based-care platforms, private equity has built numerous home health, home care, and hospice platforms; consolidation has been steady, with platforms acquiring agencies as tuck-ins and acquiring larger agencies as new platforms or fold-ins.
Large national home health and hospice companies, acquiring for geographic expansion, census, licensure (especially CON), and clinical capacity.
Payers and managed care organizations, building or buying care-at-home capabilities to manage cost and outcomes for their members, this has been a major driver of demand.
Health systems, acquiring or partnering with home health and hospice agencies to extend the care continuum and manage post-acute spend.
Regional consolidators and individual operator-buyers, for smaller agencies.

Note: several buyers in CT’s network have explicit mandates for home health, contract therapy, geriatric care, pediatric home health, and related home-based-care services, this is a vertical where we have active demand.

We have buyers for home health, home care, and hospice businesses. CT works with a network of 100+ active capital partners, private equity firms, family offices, strategic acquirers, and search funders, and several of them have stated mandates to acquire home health, home care, and hospice businesses. The multiples, buyer types, and dynamics on this page reflect those mandates plus current public M&A data, they are informed starting points, not guarantees; your outcome depends on the specifics. With the buyer-paid model, sellers pay no advisory fee, the buyer pays at closing. Get a sector-adjusted estimate with our free 90-second valuation tool.

How to prepare a home health agency for sale

Clean up billing and minimize audit/survey risk. Review your PEPPER report and address outlier metrics, clear survey deficiencies, document your coding and OASIS practices, and (for hospice) get your length-of-stay and live-discharge metrics in a defensible place. This is the biggest controllable value lever and the biggest diligence area.
Diversify referral sources, reduce reliance on any single hospital, SNF, physician group, or facility; document your referral base and conversion.
Document and improve payer mix, show the Medicare/Medicaid/insurance/private-pay breakdown by segment, and where possible shift toward higher-margin payers.
Stabilize census and document trends; show admissions, discharges, average daily census, and recertification patterns.
Strengthen caregiver/clinician recruiting and retention, document your hiring funnel, turnover, fill rates, and use of agency/contract labor.
Get your licensure and CON status documented and current, in CON states this is a material asset, make sure it’s clean and transferable.
Improve quality scores where you can, star ratings and survey history affect both valuation and buyer appetite.
Clean financials, accrual accounting, normalized owner comp, documented add-backs, 2-3 year review, and clear metrics by segment and payer.

What kills home health and hospice deals in diligence

Billing and audit exposure, PEPPER outliers, ADR/RAC findings, OASIS or coding problems; for hospice, length-of-stay or live-discharge outliers and eligibility-documentation gaps
Survey deficiencies, condition-level findings, or a poor survey history
Referral-source concentration, one hospital or facility driving most admissions
Census decline or volatility without a clear explanation
Caregiver/clinician shortages, high turnover, heavy reliance on expensive agency labor
Payer mix that’s heavily thin-margin Medicaid with rate risk
Licensure/CON problems, lapsed, non-transferable, or in question
Compliance flags, kickback exposure on referral arrangements, marketing-practice issues
Sloppy financials that don’t normalize owner comp or break out segment/payer economics

The process: first conversation to close

Off-market to a PE-backed home-based-care platform, large national home health/hospice company, payer, or health system: roughly 90-210 days (home health and especially hospice diligence runs longer because of the regulatory review), days 1-14 conversation/valuation/fit, days 14-30 buyer introductions, days 30-60 LOI, days 60-180 diligence (financials, billing/audit/survey review, payer and referral analysis, census, licensure/CON, staffing, compliance, change-of-ownership planning) and definitive agreement, days 150-210 close and CHOW transition. Traditional broker listings take 9-18 months. See our broker alternative guide.

Home Health Agency Valuation

What’s your home health agency worth?

Get a segment-adjusted multiple range using current 2026 transactions. We apply home-based-care-specific adjustments for segment, payer mix, census, referral diversity, staffing, licensure/CON, and quality scores.

Get a Home Health Agency Valuation →

The five pillars of how CT Acquisitions works

$0 to Sellers

Buyer pays our fee. Founders never write a check.

No Retainer

No engagement letter. No upfront cost. No exclusivity contract.

100+ Capital Partners

Search funders, family offices, lower-middle-market PE, strategics.

Sequential, Not Auction

Confidential introductions to the right buyers. No bidding war.

60-120 Day Close

Not 9-12 months. Not 18 months. Months, not years.

No Pitch · No Pressure

Considering selling your home health agency?

Tell us about your agency, segment (home health, home care, hospice), payer mix, census, referral sources, licensure, EBITDA. We have buyers actively acquiring home-based-care providers, and we’ll discuss what yours is worth and which buyers fit. No engagement letter, no retainer, no obligation.

Start a Confidential Conversation →

Frequently asked questions

How much is my home health agency worth?

It depends on the segment. Private-duty home care agencies typically sell for 4x to 8x EBITDA. Medicare-certified skilled home health agencies sell for roughly 7x to 9.5x EBITDA for quality mid-market agencies (smaller agencies 4x-7x, large multi-state platforms higher). Hospice agencies sell for roughly 9x to 12.5x EBITDA, the highest-multiple segment. Within each segment, payer mix, billing/audit risk profile, scale and density, census stability, referral-source diversity, caregiver/clinician retention, state licensure/CON value, and quality scores swing the number. Use our free valuation tool for a segment-adjusted estimate.

What makes a home health agency more valuable?

Being in a higher-multiple segment (hospice > skilled home health > private-duty care); a favorable payer mix (Medicare/hospice and private-pay/insurance over thin-margin Medicaid); a clean billing and audit/survey risk profile (no PEPPER outliers, clean survey history, defensible coding and, for hospice, length-of-stay/live-discharge metrics); scale and geographic density; stable census with diversified referral sources; strong caregiver and clinician recruiting and retention; valuable and transferable state licensure (especially certificate of need in CON states); good quality scores; and clean accrual financials with normalized owner comp and segment/payer-level economics. The billing/audit/survey cleanup is the biggest controllable lever.

Who is buying home health agencies in 2026?

PE-backed home-based-care platforms (private equity has built numerous home health, home care, and hospice platforms, with steady consolidation); large national home health and hospice companies expanding geography, census, and licensure; payers and managed care organizations building care-at-home capabilities (a major demand driver); health systems extending the care continuum and managing post-acute spend; and regional consolidators and individual operator-buyers for smaller agencies. CT also has buyers in its network with explicit mandates for home health, contract therapy, geriatric care, and pediatric home health.

Why does hospice command higher multiples than home health?

Hospice benefits from favorable demographics (an aging population), a per-diem Medicare payment model that produces strong margins at scale, relatively predictable economics, and intense competition among PE-backed platforms, national companies, and payers to acquire scarce well-run assets. That combination pushes quality hospice multiples to roughly 9x to 12.5x EBITDA, above skilled home health (~7x-9.5x) and well above private-duty home care (~4x-8x). The trade-off is that hospice diligence is especially rigorous on regulatory and billing risk, length of stay, live discharges, eligibility documentation, because of the enforcement environment, so a clean compliance profile is essential to capturing the premium.

Does certificate of need (CON) affect what my home health agency is worth?

Yes, materially, in states that have CON requirements for home health or hospice. In a CON state, the license itself is a scarce, valuable asset because it limits new competitor entry, so a clean, transferable CON-backed license adds real value beyond the operating business, and buyers will pay for that scarcity and the protected market position. In non-CON states, the license is still required but doesn’t carry the same scarcity premium. Either way, make sure your licensure is current, in good standing, and transferable, and understand the change-of-ownership requirements in your state, because licensure problems are a common deal killer.

How do I increase the value of my home health agency?

Clean up billing and minimize audit/survey risk (review PEPPER, clear survey deficiencies, document coding/OASIS practices, and for hospice get length-of-stay and live-discharge metrics defensible, the biggest controllable lever); diversify referral sources; document and improve payer mix; stabilize and document census; strengthen caregiver/clinician recruiting and retention and reduce agency-labor reliance; get licensure and CON status documented, current, and transferable; improve quality scores; and get clean accrual financials with normalized owner comp and segment/payer economics. The billing/audit/survey work is the highest-impact item and can be materially improved in 12-24 months.

How long does it take to sell a home health agency?

Traditional broker-listed agencies typically take 9-18 months. Off-market sales to PE-backed home-based-care platforms, national home health/hospice companies, payers, or health systems typically take 90-210 days, somewhat longer than other healthcare-services deals because home health and especially hospice diligence includes a thorough regulatory and billing review and the change-of-ownership process takes time. The buyer being pre-qualified and actively looking in your segment and geography is what keeps it to months rather than the year-plus a broad broker listing takes.

Do I need a broker to sell my home health agency?

For a small private-duty agency, a healthcare-focused business broker can work but charges 8-15% commissions. For Medicare-certified home health and hospice agencies, a buyer-paid sell-side advisor with relationships across the PE-backed home-based-care platforms, national home health/hospice companies, payers, and health systems usually produces better outcomes, higher multiples, better-matched buyers, faster close, no seller fee (the buyer pays at closing). Some sellers sell directly to a known platform with just healthcare transactional counsel, but a competitive process almost always lifts the price, especially in hospice where buyer demand is intense.